Voleon Capital Management LP Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Voleon Capital Management LP acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 57,922 shares of the medical device company's stock, valued at approximately $4,505,000.

A number of other institutional investors have also recently bought and sold shares of DXCM. Norges Bank acquired a new position in DexCom in the 4th quarter valued at approximately $385,367,000. Congress Asset Management Co. increased its stake in shares of DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after acquiring an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD purchased a new stake in shares of DexCom during the fourth quarter worth $96,507,000. Northern Trust Corp boosted its position in DexCom by 22.2% during the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock valued at $594,455,000 after purchasing an additional 710,858 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. The trade was a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares of the company's stock, valued at $26,183,401.02. This trade represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 66,926 shares of company stock valued at $4,734,384. 0.32% of the stock is currently owned by corporate insiders.

DexCom Stock Up 0.2 %

DXCM stock opened at $71.30 on Wednesday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $132.26. The company has a market cap of $27.96 billion, a PE ratio of 49.86, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The business's 50-day simple moving average is $72.35 and its 200 day simple moving average is $76.70. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on DXCM shares. Canaccord Genuity Group boosted their price target on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and increased their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley raised their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Mizuho began coverage on DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and an average target price of $99.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.